FHD-286 in Subjects With Metastatic Uveal Melanoma

Stopped early · Phase 1

Conditions studied: Metastatic Uveal Melanoma

In brief

This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).

Key facts

Study ID

NCT04879017

Run by

Foghorn Therapeutics Inc.

People needed

76

Starts

2021-05-11

Expected to finish

2023-11-30

Last updated by the study team

2024-04-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• The Angeles Clinic and Research Institute — Los Angeles, California, United States
• University of Miami Health System, Sylvester Comprehensive Cancer Center — Miami, Florida, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Columbia University, Herbert Irving Comprehensive Cancer Center — New York, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Sidney Kimmel Cancer Center - Jefferson Health — Philadelphia, Pennsylvania, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Institute Curie Hospital — Paris, France
• Leiden University Medical Center — Leiden, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.